Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

EGAS00001000333-sc-20141112 - samples

ABSTRACT: Patient (who has had multiple malignancies) has previously been found to harbour a pathogenic p53 variant which is probably mosaic. This finding is based on exome sequencing performed elsewhere. In this study we will resequence the locus in question to ascertain whether the variant is indeed mosaic.

PROVIDER: EGAD00001001062 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Similar Datasets

Multiple Malignancy Familial Comparison

Project description:Patient (who has had multiple malignancies) has previously been found to harbour a pathogenic p53 variant which is probably mosaic. This finding is based on exome sequencing performed elsewhere. In this study we will resequence the locus in question to ascertain whether the variant is indeed mosaic.

| EGAS00001000333 | EGA

H2A.Z knockdown RNAseq

Project description:This experiment seeks to ascertain the transcriptional changes in the adult mouse hippocampus (CA1 subregion) that occur following viral knockdown of the histone variant H2A.Z. We are especially interested in understanding the role of this histone variant in memory formation and memory maintenance in the adult central nervous system.

2014-09-09 | GSE58797 | GEO

Evaluation of copy number alterations in the Ewing's Sarcoma cell line SKES1 with Affymetrix 500k SNP microarray

2011-08-01 | GSE20356 | GEO

Homo sapiens

Project description:Reference standards for mosaic variant detection

| PRJNA758606 | ENA

Reference Standards for Mosaic Variant Detection

Project description:Reference Standards for Mosaic Variant Detection

| PRJNA1007404 | ENA

Reference Standards for Mosaic Variant Detection

Project description:Reference Standards for Mosaic Variant Detection

| PRJNA1007405 | ENA

p53-mediated hematopoietic stem and progenitor cell competition

Project description:Cell competition was originally described in Drosophila as a process for selection of the fittest cells. Using genetic mosaic mouse models and bone marrow chimeras, we have characterized a form of cell competition that selects for the least damaged cells. This competition is controlled by p53 but is distinct from the classical p53-mediated DNA damage response: it persists for months, is specific to the hematopoietic stem and progenitor cells, and depends on the relative rather than absolute level of p53 in competing cells. The competition appears to be mediated by a non-cell autonomous induction of growth arrest and senescence-related gene expression in outcompeted cells with higher p53 activity. p53-mediated cell competition of this type could potentially contribute to the clonal expansion of incipient cancer cells. This microarray experiment is aimed at identification of candidate genes that mediate this competition. It compares mRNA expression patterns of HSCs with different levels of p53 activity in either competitive or non-competitive conditions (isolated from either wild type, mutant p53, or mosaic wt/mutant p53 mice (R26-mp53mice) after irradiation).

2010-04-01 | GSE20912 | GEO

Comparison of irradiation-induced genes from freshly isolated bone-adherent mesenchymal cells of p53-WT and p53-null mice

Project description:Gene expression profiling was determined in BAMC isolated from non-irradiated and irradiated p53-null and p53-WT mice. We selected strongly expressed genes in p53-WT compared to p53-null BAMC. They belonged to different pathways.Also, a number of genes coded secreting proteins that , probably, were responsible for the improved hematopoiesis in p53-null mice.

2018-07-25 | GSE117625 | GEO

Common activities and predictive gene signature identified for genetic hypomorphs of TP53

Project description:Mutational inactivation of TP53 is a common event in cancer. Germline mutations in TP53 that inactivate this protein also occur in Li Fraumeni syndrome, which predisposes to early-onset cancer. In addition, there are dozens of other germline variants in TP53 that do not completely inactivate the function of this protein. In many cases studies have shown strong support for an impact of these lesser-functioning hypomorphs with increased cancer risk in humans and mouse models; however, the majority of these hypomorphs have yet to be categorized as pathogenic in clinical genetics databases. There is thus need for a functional assay to distinguish lesser-functioning hypomorphic p53 variants from wild type p53, or benign, fully-functional, variants. We report the surprising finding that two different African-centric genetic hypomorphs of p53, which occur in distinct functional domains of the protein, share common activities. We show that the Pro47Ser variant in the transactivation domain and the Tyr107His variant in the DNA binding domain both share increased propensity to misfold into a conformation specific for mutant p53. Moreover, cells and tissues with these variants show increased NF-B activity. We have identified a common gene signature from unstressed lymphocyte cell lines that is shared between these two, and other, genetic missense hypomorphs of TP53. We show that this gene signature successfully distinguishes wild type p53 and a benign p53 variant from lesser-functioning hypomorphic variants. These findings should allow us to better understand how hypomorphic variants contribute to cancer risk, and to better inform cancer risk in hypomorph carriers.

2023-03-01 | GSE209837 | GEO

Evaluation of copy number alterations in the Ewing's Sarcoma cell line SKES1 with Affymetrix 500k SNP microarray

Project description:As a result of a copy number alterations study (BAC-microarray), the SKES1 cell line was found to harbour a microdeletion in 16q23.2 SNP microarrays were applied in order to accurately delimit this alteration, finding a microdeletion of 1.04 Megabases in size. Affymetrix SNP arrays were performed according to the manufacturer's directions on DNA extracted from a SKES1 cell culture

2011-07-31 | E-GEOD-20356 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data